CapsoVision posts 10% revenue growth as AI Highlights eyes FDA clearance
CapsoVision has reported second-quarter 2026 revenue of $3.6 million, a 10% year-on-year increase, as the Saratoga-based medical technology company pressed ahead with the commercial rollout of its AI-assisted reading feature and advanced a colon imaging pipeline product toward regulatory submission.
The top-line growth was driven by a 13% rise in the number of CapsoCam Plus capsules sold, though the company noted a roughly 3% decline in average selling price over the same period, reflecting competitive pricing pressure in the capsule endoscopy market. Gross margin slipped to 51% from 55% a year earlier, partly due to increased customs and tariff costs following changes to US trade policy introduced at the start of 2026. Operating expenses rose sharply to $9.5 million from $6.5 million in Q2 2025, with the increase attributed to clinical study costs, non-recurring engineering work on a Canon development project, and public-company overheads. The net loss for the quarter widened to $7.5 million.
AI launch and regulatory path
CapsoVision commercially launched AI Highlights, its AI-assisted workflow tool for reviewing small bowel capsule endoscopy studies, in the European Union and other international markets during the quarter. The company said it anticipates FDA 510(k) clearance of the feature by the end of Q3 2026, with a US commercial launch to follow shortly thereafter. The company's chief executive, Johnny Wang, said interest from US customers awaiting the domestic launch remains strong.
The pipeline is also advancing on a second front. CapsoCam Colon, designed for non-invasive polyp detection in the lower GI tract, remains on track for a 510(k) submission in Q4 2026. An ongoing clinical study for CapsoCam UGI, targeting pancreatic cancer detection, continues to enrol patients. The company also appointed David S. Shields, M.D., to its board of directors, effective 1 July 2026.
Cash and cash equivalents stood at $9.1 million as of 30 June 2026. To bolster its liquidity position, CapsoVision entered into an at-the-market equity offering programme with Cantor, providing access to up to $100 million in additional capital. The accumulated deficit reached $170 million by the end of the quarter.
Market context
The capsule endoscopy sector is undergoing a meaningful technology transition, with AI-assisted image review emerging as a key competitive differentiator. CapsoVision's principal competitor, Medtronic's PillCam franchise, has held a dominant share of the global market for many years, while Olympus and several smaller entrants have added lateral pressure. Against this backdrop, CapsoVision's panoramic imaging design and cloud-based retrieval system represent a distinct engineering approach, though the company's ability to convert that differentiation into pricing power has so far been constrained.
The appetite for AI-enabled diagnostic tools in gastrointestinal endoscopy is growing across both the US and European markets, supported by clinician demand for workflow efficiency and payer interest in reducing the cost of downstream colonoscopy referrals. A successful FDA clearance for AI Highlights in the coming weeks would give CapsoVision a commercially relevant feature advantage in its home market at a time when it is also seeking to extend its platform into the colon and upper GI segments. How quickly that translates into revenue will depend on reimbursement pathways and the pace of adoption within the large hospital systems and gastroenterology networks the company says are already showing momentum.